Overview

12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa

Status:
Completed

Trial end date:
2003-06-01

Target enrollment:

Participant gender:

Summary

12-week, double-blind, placebo-controlled, multicenter, randomized study designed to evaluate the safety and efficacy of 40 mg/day istradefylline compared with placebo in subjects with OFF phenomena advanced PD who were treated with levodopa/carbidopa.

Phase:

Phase 2

Details

Lead Sponsor:

Kyowa Kirin Pharmaceutical Development, Inc.
Kyowa Kirin, Inc.

Treatments:

Carbidopa
Istradefylline
Levodopa